Prostate Cancer Screening Maple Heights OH

Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Maple Heights, OH who provide prostate cancer screening.

M Ali Tirgan, MD
440-786-8000
88 Center Rd Ste 210
Cleveland, OH
Min Chul Oh, MD
410-355-0868
26900 Cedar Rd
Beachwood, OH
Deborah K Erwin-Nas, MS
216-991-6692
3633 Lytle Rd
Shaker Heights, OH
Gary Arnold Schnur, MD
216-839-2990
26900 Cedar Rd
Beachwood, OH
James Norman Lowder, MD
28779 Orangewood Dr
Cleveland, OH
Jay Phillip Ciezki, MD
26900 Cedar Rd
Beachwood, OH
John F Greskovich Jr, MD
216-445-8285
3909 Orange Pl
Beachwood, OH
Samir Abraksia, MD
216-491-6438
4200 Warrensville Center Rd
Warrensville Heights, OH
Jerald Katcher, MD
3909 Orange Pl
Beachwood, OH
Carlos Victor Rozenbom, MD
330-452-9911
3909 Orange Pl
Beachwood, OH
Data Provided by:
 

All about the PSA Test

The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.

Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.

An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.

There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...

Click here to read more from Quality Health